Navigation Links
A first in front line immunity research
Date:7/21/2013

Monash University researchers have gained new insight into the early stages of our immune response, providing novel pathways to develop treatments for diseases from multiple sclerosis to cancer.

In a study published today in Nature Immunology, a team of researchers led by Professor Paul Hertzog, of the Monash Institute of Medical Research (MIMR) and Professor Jamie Rossjohn, of the School of Biomedical Sciences, have characterised for the first time how interferon beta (IFNβ) proteins bind to cells and activate an immune response.

Produced when viral and bacterial infections are detected, interferon proteins are vital to the body's defences. They activate immune cells, such as macrophages, can interfere with virus replication, and can boost cells' resilience to infection. They also enhance later immune responses to cancers and other stresses.

There are at least 20 subtypes of interferons that are produced at different stages of the immune response. They appear to have different functions, but these functions and their triggers are generally not well understood. The mapping of INFβ - cell interaction is a breakthrough in the field.

Professor Hertzog of MIMR's Centre for Innate Immunity and Infectious Diseases said interferon function was vital for developing and refining therapies for incurable diseases such as lupus and multiple sclerosis.

"Interferon therapy is useful in treating a number of diseases; however these treatments have dose-limiting side effects. Further, interferons appear to drive some autoimmune diseases, raising the prospect of interferon blockers as treatment," Professor Hertzog said.

"The more refined our understanding of interferon function, the more we can tailor treatments to optimise effectiveness - whether by boosting or blocking their actions."

Lead author on the paper, Dr Nicole de Weerd, also of the Centre for Innate Immunity and Infectious Diseases, said the research provided new pathways for rational drug design.

"We found that when IFNβ binds to a cell, it transmits an unusual signal that seems linked to some of the toxic side effects of interferon therapy, like sepsis. This provides a promising avenue to pursue more selective activation of interferon action," Dr de Weerd said.

Professor Rossjohn and Julian Vivian from the Department of Biochemistry and Molecular Biology collaborated closely on determining the IFNβ interactions at the molecular level.

"During this seven-year study, we have had great support from the Australian Synchrotron," Professor Rossjohn said.


'/>"/>

Contact: Emily Walker
emily.walker@monash.edu
61-399-034-844
Monash University
Source:Eurekalert

Related biology news :

1. Kessler Foundation implements Ekso Bionics first commercial robotic exoskeleton
2. Research reveals first evidence of hunting by prehistoric Ohioans
3. First model of how buds grow into leaves
4. American College of Rheumatology releases first classification criteria for polymyalagia rheumatica
5. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
6. First complete full genetic map of promising energy crop
7. FirstMark Announces New Hire Jay Houtman as Southeast Regional Sales Manager
8. FirstMark Exhibiting at the Inaugural Atlanta Clinical Cardiology Update
9. New technology tracks sparrow migration for first time from California to Alaska
10. First mass extinction linked to marine anoxia
11. Scientists complete first-ever emperor penguin count from space
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2016)... 2016 Perimeter Surveillance & Detection ... Physical Infrastructure, Support & Other Service  The ... offers comprehensive analysis of the global Border Security ... revenues of $17.98 billion in 2016. Now: ... leader in software and hardware technologies for advanced video ...
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour ... from the Q1 wave of its quarterly wearables survey. ... receptivity to a program where they would receive discounts ... company. "We were surprised to see that ... LaColla , CEO of Troubadour Research, "primarily because there ...
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration ... security to access and transact across channels. Using ...
Breaking Biology News(10 mins):
(Date:6/22/2016)... 2016 Cell Applications, Inc. and StemoniX ... produce up to one billion human induced pluripotent ... week. These high-quality, consistent stem cells enable researchers ... spend more time doing meaningful, relevant research. This ... manufacturing process that produces affordable, reliable HiPSC for ...
(Date:6/22/2016)...   StockNewsNow.com , The Official MicroCap News Source™, ... Nader Pourhassan , President & CEO of CytoDyn Inc. ... development and potential commercialization of humanized monoclonal antibodies for ... the company,s website (see here: www.CytoDyn.com ). The ... , 2016, at the LD Micro Invitational in ...
(Date:6/22/2016)... ... , ... New light-based technologies that facilitate a “look inside” the human body ... compact, wearable devices for point-of-care diagnostics as well as powerful new systems that provide ... visionary future directions are detailed in a new open-access article by Antonio Pifferi and ...
(Date:6/22/2016)... ALBANY, N.Y. , June 22, 2016 ... Molecular Research, Inc. (NASDAQ: AMRI ) ... to produce and sell the first commercially available ... standard is manufactured using Teewinot,s patented biosynthetic processes. ... biosynthetic genes in microorganisms for efficient production of ...
Breaking Biology Technology: